MEI Pharma Inc. | Cash Flow


No data

About MEI Pharma

View Profile
Address
3611 Valley Centre Drive
San Diego California 92130
United States
Employees -
Website http://www.meipharma.com
Updated 07/08/2019
MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor.